Shifting incidence and survival of epithelial ovarian cancer (1995-2014): A SurvMark-2 study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Shifting incidence and survival of epithelial ovarian cancer (1995-2014) : A SurvMark-2 study. / Cabasag, Citadel J; Arnold, Melina; Rutherford, Mark; Ferlay, Jacques; Bardot, Aude; Morgan, Eileen; Butler, John; O'Connell, Dianne L; Nelson, Gregg; Høgdall, Claus; Schnack, Tine; Gavin, Anna; Elwood, Mark; Hanna, Louise; Gourley, Charlie; De, Prithwish; Saint-Jacques, Nathalie; Mørch, Lina Steinrud; Woods, Ryan R; Altman, Alon D; Sykes, Peter; Cohen, Paul A; McNally, Orla; Møller, Bjørn; Walsh, Paul; Morrison, David S; Bray, Freddie; Soerjomataram, Isabelle.
I: International Journal of Cancer, Bind 152, Nr. 9, 2023, s. 1763-1777.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Shifting incidence and survival of epithelial ovarian cancer (1995-2014)
T2 - A SurvMark-2 study
AU - Cabasag, Citadel J
AU - Arnold, Melina
AU - Rutherford, Mark
AU - Ferlay, Jacques
AU - Bardot, Aude
AU - Morgan, Eileen
AU - Butler, John
AU - O'Connell, Dianne L
AU - Nelson, Gregg
AU - Høgdall, Claus
AU - Schnack, Tine
AU - Gavin, Anna
AU - Elwood, Mark
AU - Hanna, Louise
AU - Gourley, Charlie
AU - De, Prithwish
AU - Saint-Jacques, Nathalie
AU - Mørch, Lina Steinrud
AU - Woods, Ryan R
AU - Altman, Alon D
AU - Sykes, Peter
AU - Cohen, Paul A
AU - McNally, Orla
AU - Møller, Bjørn
AU - Walsh, Paul
AU - Morrison, David S
AU - Bray, Freddie
AU - Soerjomataram, Isabelle
N1 - © 2022 International Agency for Research on Cancer. International Agency for Research on Cancer retains copyright and all other rights in the manuscript of this article as submitted for publication.
PY - 2023
Y1 - 2023
N2 - The aim of the study is to provide a comprehensive assessment of incidence and survival trends of epithelial ovarian cancer (EOC) by histological subtype across seven high income countries (Australia, Canada, Denmark, Ireland, New Zealand, Norway and the United Kingdom). Data on invasive EOC diagnosed in women aged 15 to 99 years during 1995 to 2014 were obtained from 20 cancer registries. Age standardized incidence rates and average annual percentage change were calculated by subtype for all ages and age groups (15-64 and 65-99 years). Net survival (NS) was estimated by subtype, age group and 5-year period using Pohar-Perme estimator. Our findings showed marked increase in serous carcinoma incidence was observed between 1995 and 2014 among women aged 65 to 99 years with average annual increase ranging between 2.2% and 5.8%. We documented a marked decrease in the incidence of adenocarcinoma "not otherwise specified" with estimates ranging between 4.4% and 7.4% in women aged 15 to 64 years and between 2.0% and 3.7% among the older age group. Improved survival, combining all EOC subtypes, was observed for all ages combined over the 20-year study period in all countries with 5-year NS absolute percent change ranging between 5.0 in Canada and 12.6 in Denmark. Several factors such as changes in guidelines and advancement in diagnostic tools may potentially influence the observed shift in histological subtypes and temporal trends. Progress in clinical management and treatment over the past decades potentially plays a role in the observed improvements in EOC survival.
AB - The aim of the study is to provide a comprehensive assessment of incidence and survival trends of epithelial ovarian cancer (EOC) by histological subtype across seven high income countries (Australia, Canada, Denmark, Ireland, New Zealand, Norway and the United Kingdom). Data on invasive EOC diagnosed in women aged 15 to 99 years during 1995 to 2014 were obtained from 20 cancer registries. Age standardized incidence rates and average annual percentage change were calculated by subtype for all ages and age groups (15-64 and 65-99 years). Net survival (NS) was estimated by subtype, age group and 5-year period using Pohar-Perme estimator. Our findings showed marked increase in serous carcinoma incidence was observed between 1995 and 2014 among women aged 65 to 99 years with average annual increase ranging between 2.2% and 5.8%. We documented a marked decrease in the incidence of adenocarcinoma "not otherwise specified" with estimates ranging between 4.4% and 7.4% in women aged 15 to 64 years and between 2.0% and 3.7% among the older age group. Improved survival, combining all EOC subtypes, was observed for all ages combined over the 20-year study period in all countries with 5-year NS absolute percent change ranging between 5.0 in Canada and 12.6 in Denmark. Several factors such as changes in guidelines and advancement in diagnostic tools may potentially influence the observed shift in histological subtypes and temporal trends. Progress in clinical management and treatment over the past decades potentially plays a role in the observed improvements in EOC survival.
U2 - 10.1002/ijc.34403
DO - 10.1002/ijc.34403
M3 - Journal article
C2 - 36533660
VL - 152
SP - 1763
EP - 1777
JO - International Journal of Cancer
JF - International Journal of Cancer
SN - 0020-7136
IS - 9
ER -
ID: 334013337